Healius Limited · ASX:HLS
Healius — Merger or Acquisition (September 2024)
8 slides from Healius's merger presentation, Sep 23, 2024
Slide 1: Sale of Lumus Imaging Investor Presentation
Sale of Lumus Imaging Investor Presentation Paul Anderson Chief Executive Officer & Managing Director 23 September 2024 1
Slide 2: Disclaimer
Disclaimer This presentation may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Healius Limited. Readers are cautioned not to place undue reliance on forward-looking st
Slide 3: Introduction
Introduction The sale of Lumus follows a strategic review of Healius’ structure and assets with the objective of maximising shareholder value and ensuring a sustainable capital structure that will support investment and ongoing growth Sale of Lumus Imaging Healius post the sale of Lumus Improved bal
Slide 4: Binding agreement for the sale of Lumus Imaging
Binding agreement for the sale of Lumus Imaging Valuation and proceeds Approvals Timing Business separation • Transaction fully values Lumus • The sale is subject to customary • Completion is expected in 1Q • To support the separation and and represents: conditions, including approval CY2025 ensure
Slide 5: Healius post the sale of Lumus
Healius post the sale of Lumus Pro forma impact on FY24 metrics FY24 FY24 PF • Following completion of the transaction, Healius will continue to be a leading for sale provider of pathology services in Australia with a rapidly growing bioanalytical of Lumus lab services business, and significantly re
Slide 6: Significantly improved balance sheet
Significantly improved balance sheet On completion Healius will be in a material net cash position, providing capacity to execute the new strategy in its continuing operations and for capital management Pro forma impact on FY24 metrics Estimated cash proceeds FY24 PF for sale of FY24 Lumus FY24 $m $
Slide 7: Capital management
Capital management Following completion of the transaction, Healius intends to return surplus proceeds to shareholders • Estimated cash proceeds in excess of $800 million after lease liabilities, transaction costs and purchase price adjustments • Completion timing will determine the final proceeds •
Slide 8: Questions
Questions 8